Processa Pharmaceuticals Inc

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Vero Beach, Florida, founded in 2015. It develops cancer therapy drugs that modify existing FDA-approved oncology drugs to alter their metabolism and/or distribution while preserving their mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine in a Phase 2 trial for metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors, and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan in preclinical trials for lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs: PCS499, an oral tablet of the deuterated analog of pentoxifylline that completed a Phase 2b trial for primary glomerular diseases including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that completed a Phase 2 trial for gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited.

Biotech & Genomic Medicine▲impact 4

Processa Pharmaceuticals acquires Vidya Therapeutics and secures $200 million private placement to advance BTK inhibitor VT-7208

Processa Pharmaceuticals has acquired Vidya Therapeutics and concurrently secured approximately $200 million in a private placement to advance VT-7208, a next-generation BTK inhibitor, across multiple disease areas. The private placement was committed by a syndicate of leading healthcare institutional investors including Bain Capital Life Sciences, Janus Henderson Investors, and RA Capital Management. Proceeds are expected to fund operations into the second half of 2029 and through key clinical milestones, including top-line data from Phase 2 proof-of-concept studies for food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis. The acquisition brings Vidya's lead asset VT-7208 into Processa's pipeline, with Phase 2 studies in food allergy and chronic spontaneous urticaria expected to begin in the second half of 2026 and a relapsing multiple sclerosis study in the first half of 2027. Processa will host an investor webcast on July 29, 2026, at 8:30 a.m. Eastern Time.

PCSA ▲

Biotech & Genomic Medicine

GlobeNewswire·51dRead more →